These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10737744)

  • 1. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
    Bromidge SM; Dabbs S; Davies DT; Davies S; Duckworth DM; Forbes IT; Gaster LM; Ham P; Jones GE; King FD; Mulholland KR; Saunders DV; Wyman PA; Blaney FE; Clarke SE; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Trail B; Riley GJ; Wood MD
    J Med Chem; 2000 Mar; 43(6):1123-34. PubMed ID: 10737744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.
    Bromidge SM; Dabbs S; Davies S; Duckworth DM; Forbes IT; Jones GE; Jones J; King FD; Saunders DV; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Riley GJ; Trail B; Wood MD
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1863-6. PubMed ID: 10969986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.
    Bromidge SM; Dabbs S; Davies DT; Duckworth DM; Forbes IT; Ham P; Jones GE; King FD; Saunders DV; Starr S; Thewlis KM; Wyman PA; Blaney FE; Naylor CB; Bailey F; Blackburn TP; Holland V; Kennett GA; Riley GJ; Wood MD
    J Med Chem; 1998 May; 41(10):1598-612. PubMed ID: 9572885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety.
    Wood MD; Reavill C; Trail B; Wilson A; Stean T; Kennett GA; Lightowler S; Blackburn TP; Thomas D; Gager TL; Riley G; Holland V; Bromidge SM; Forbes IT; Middlemiss DN
    Neuropharmacology; 2001 Aug; 41(2):186-99. PubMed ID: 11489455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the selectivity and metabolic stability of the serotonin 5-HT(1A) ligand, S 15535: a series of cis- and trans-2-(arylcycloalkylamine) 1-indanols.
    Peglion JL; Goument B; Despaux N; Charlot V; Giraud H; Nisole C; Newman-Tancredi A; Dekeyne A; Bertrand M; Genissel P; Millan MJ
    J Med Chem; 2002 Jan; 45(1):165-76. PubMed ID: 11754589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.
    Dekeyne A; Mannoury la Cour C; Gobert A; Brocco M; Lejeune F; Serres F; Sharp T; Daszuta A; Soumier A; Papp M; Rivet JM; Flik G; Cremers TI; Muller O; Lavielle G; Millan MJ
    Psychopharmacology (Berl); 2008 Sep; 199(4):549-68. PubMed ID: 18523738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists.
    Ennis MD; Hoffman RL; Ghazal NB; Olson RM; Knauer CS; Chio CL; Hyslop DK; Campbell JE; Fitzgerald LW; Nichols NF; Svensson KA; McCall RB; Haber CL; Kagey ML; Dinh DM
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2369-72. PubMed ID: 12824036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
    Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
    J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.
    Kennett GA; Wood MD; Bright F; Cilia J; Piper DC; Gager T; Thomas D; Baxter GS; Forbes IT; Ham P; Blackburn TP
    Br J Pharmacol; 1996 Feb; 117(3):427-434. PubMed ID: 8821530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat.
    Monti JM; Jantos H
    Eur J Pharmacol; 2006 Dec; 553(1-3):163-70. PubMed ID: 17059817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.
    Vickers SP; Easton N; Malcolm CS; Allen NH; Porter RH; Bickerdike MJ; Kennett GA
    Pharmacol Biochem Behav; 2001; 69(3-4):643-52. PubMed ID: 11509227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist.
    Kennett GA; Wood MD; Glen A; Grewal S; Forbes I; Gadre A; Blackburn TP
    Br J Pharmacol; 1994 Mar; 111(3):797-802. PubMed ID: 7912626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.
    Gleason SD; Lucaites VL; Shannon HE; Nelson DL; Leander JD
    Behav Pharmacol; 2001 Dec; 12(8):613-20. PubMed ID: 11856898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors.
    McMahon LR; Cunningham KA
    Neuropsychopharmacology; 2001 Mar; 24(3):319-29. PubMed ID: 11166521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
    Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
    Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT₇ receptor antagonist activity.
    Volk B; Gacsályi I; Pallagi K; Poszávácz L; Gyönös I; Szabó E; Bakó T; Spedding M; Simig G; Szénási G
    J Med Chem; 2011 Oct; 54(19):6657-69. PubMed ID: 21859099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.
    Forbes IT; Ham P; Booth DH; Martin RT; Thompson M; Baxter GS; Blackburn TP; Glen A; Kennett GA; Wood MD
    J Med Chem; 1995 Jul; 38(14):2524-30. PubMed ID: 7629791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation.
    Chłoń-Rzepa G; Zmudzki P; Satała G; Duszyńska B; Partyka A; Wróbel D; Jastrzębska-Więsek M; Wesołowska A; Bojarski AJ; Pawłowski M; Zajdel P
    Pharmacol Rep; 2013; 65(1):15-29. PubMed ID: 23563020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents.
    Abou-Gharbia MA; Childers WE; Fletcher H; McGaughey G; Patel U; Webb MB; Yardley J; Andree T; Boast C; Kucharik RJ; Marquis K; Morris H; Scerni R; Moyer JA
    J Med Chem; 1999 Dec; 42(25):5077-94. PubMed ID: 10602693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin2C ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease.
    Navailles S; Lagière M; Roumegous A; Polito M; Boujema MB; Cador M; Dunlop J; Chesselet MF; Millan MJ; De Deurwaerdère P
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):593-606. PubMed ID: 22717119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.